1α,25(OH)2D3 Radiosensitizes Cancer Cells by Activating the NADPH/ROS Pathway

The radioresistance of tumors affect the outcome of radiotherapy. Accumulating data suggest that 1 alpha,25(OH)(2)D(3)is a potential anti-oncogenic molecule in various cancers. In the present study, we investigated the radiosensitive effects and underlying mechanisms of 1 alpha,25(OH)(2)D(3)in vitroandin vivo. We found that 1 alpha,25(OH)(2)D(3)enhanced the radiosensitivity of lung cancer and ovarian cancer cells by promoting the NADPH oxidase-ROS-apoptosis axis. Compared to the group that only received radiation, the survival fraction and self-renewal capacity of cancer cells treated with a combination of 1 alpha,25(OH)(2)D(3)and radiation were decreased. Both apoptosis and ROS were significantly increased in the combination group compared with the radiation only group. Moreover, N-acetyl-L-cysteine, a scavenger of intracellular ROS, reversed the apoptosis and ROS induced by 1 alpha,25(OH)(2)D-3, indicating that 1 alpha,25(OH)(2)D(3)enhanced the radiosensitivity of cancer cellsin vitroby promoting ROS-induced apoptosis. Moreover, our results demonstrated that 1 alpha,25(OH)(2)D(3)promoted the ROS levelviaactivating NADPH oxidase complexes, NOX4, p22(phox), and p47(phox). In addition, knockdown of the vitamin D receptor (VDR) abolished the radiosensitization of 1 alpha,25(OH)(2)D-3, which confirmed that 1 alpha,25(OH)(2)D(3)radiosensitized tumor cells that depend on VDR. Similarly, our study also evidenced that vitamin D(3)enhanced the radiosensitivity of cancer cellsin vivoand extended the overall survival of mice with tumors. In summary, these results demonstrate that 1 alpha,25(OH)(2)D(3)enhances the radiosensitivity depending on VDR and activates the NADPH oxidase-ROS-apoptosis axis. Our findings suggest that 1 alpha,25(OH)(2)D(3)in combination with radiation enhances lung and ovarian cell radiosensitivity, potentially providing a novel combination therapeutic strategy.